Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Light-Based scanner could spot cancer without needles

NCT ID NCT05488483

Diagnosis Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a new imaging technique called multispectral optoacoustic tomography (MSOT) can visualize breast cancer and melanoma tumors. Twelve participants will have MSOT scans before their standard biopsy or treatment. The goal is to see if MSOT can detect tumors and measure oxygen levels, which might help improve cancer diagnosis in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multispectral Optoacoustic Tomography (MSOT) imaging
What this could lead to
If successful, this could lead to a new, non-invasive way to detect and monitor tumors without radiation or contrast dyes.
What could go wrong
This is a very small feasibility study with only 12 participants, so results may not apply to everyone. The technology is still experimental and may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

12 people

The number who actually took part.

Started

Jul 2022

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with a suspicious breast imaging finding detected on either mammography, ultrasound or MRI that is visible on ultrasound and therefore recommended for ultrasound-guided breast biopsy (BI-RADS 4 suspicious abnormality; BI-RADS 5, highly suggestive for malignancy) who are scheduled for ultrasound-guided breast biopsy by the Memorial Sloan Kettering Department of Radiology Breast Imaging Service will be included.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant is a female or male who is 18 years of age or older. * Participant must meet one of the following: * Suspicious breast imaging finding detected on either mammography, ultrasound, or MRI that is visible on ultrasound and therefore recommended for ultrasound-guided breast biopsy (BI-RADS 4 suspicious abnormality; BI-RADS 5, highly suggestive for malignancy) * No previous treatment for breast cancer * Diagnosis of melanoma Exclusion Criteria: * Life expectancy \< 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Melanoma

Contacts and locations

Locations

  • Helmholtz Institute (Data Analysis Only)

    Munich, Germany

  • Memorial Sloan - Kettering Cancer Center

    New York, New York, 10021, United States

  • Memorial Sloan Kettering Bergen (Consent only )

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)

    Commack, New York, 11725, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.